ES2102978T3 - Inmunoterapia tumoral empleando anticuerpos anti-idiotipicos. - Google Patents

Inmunoterapia tumoral empleando anticuerpos anti-idiotipicos.

Info

Publication number
ES2102978T3
ES2102978T3 ES88114834T ES88114834T ES2102978T3 ES 2102978 T3 ES2102978 T3 ES 2102978T3 ES 88114834 T ES88114834 T ES 88114834T ES 88114834 T ES88114834 T ES 88114834T ES 2102978 T3 ES2102978 T3 ES 2102978T3
Authority
ES
Spain
Prior art keywords
tumor
idiotipic
antibodies
antibody
idiotipic antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88114834T
Other languages
English (en)
Inventor
Ingegerd Hellstrom
Karl Frik Hellstrom
Maria S Kahn
Donna Francine Beaton
Victor K Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/116,802 external-priority patent/US4918164A/en
Application filed by Oncogen LP filed Critical Oncogen LP
Application granted granted Critical
Publication of ES2102978T3 publication Critical patent/ES2102978T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5757—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofoetal proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A METODOS QUE UTILIZAN ANTICUERPOS ANTI - IDIOTIPICOS, O FRAGMENTOS DE ESTO, PARA INMUNOTERAPIA DE TUMORES O INMUNOPROFILAXIS. LOS ANTICUERPOS ANTI - IDIOTIPICOS MONOCLONALES QUE RECONOCEN UN IDIOTIPO PRESENTE SOBRE UN SEGUNDO ANTICUERPO O SOBRE UN LINFOCITO T O UN FACTOR INMUNO SUPRESOR QUE ESTA DIRIGIDO CONTRA UN ANTIGENO TUMORAL DEFINIDO PUEDE USARSE PARA INMUNIZACION CONTRA UN TUMOR, PARA ACTIVACION O SUPRESION ANTI - TUMOR INMUNOLOGICA O PARA ACTIVACION IN VITRO DE HOFOCITOS A UTILIZAR EN INMUNOTERAPIA ADOPTIVA. LOS ANTICUERPOS ANTI - IDIOTIPICOS O FRAGMENTOS DE ESTO, PUEDEN TAMBIEN UTILIZARSE PARA CONTROLAR INDUCCION DE ANTICUERPOS EN PACIENTES QUE SUFREN INMUNIZACION TUMORAL POR ADMINISTRACION DE ANTICUERPO TUMORAL. EN OTRO ASPECTO, LA ADMINISTRACION DE LIMFOCITOS T QUE EXPRESA UN IDIOTIPO DIRIGIDO CONTRA UN ANTIGENO TUMORAL DEFINIDO PUEDE SER USADA PARA TRANSFERIR HIPERSENSIBILIDAD DE TIPO DIFERIDO AL TUMOR.
ES88114834T 1987-09-10 1988-09-09 Inmunoterapia tumoral empleando anticuerpos anti-idiotipicos. Expired - Lifetime ES2102978T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9609587A 1987-09-10 1987-09-10
US07/116,802 US4918164A (en) 1987-09-10 1987-11-04 Tumor immunotherapy using anti-idiotypic antibodies
US07/225,446 US5614610A (en) 1984-12-21 1988-07-28 Tumor immunotherapy using anti-idiotypic antibodies

Publications (1)

Publication Number Publication Date
ES2102978T3 true ES2102978T3 (es) 1997-08-16

Family

ID=27378089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88114834T Expired - Lifetime ES2102978T3 (es) 1987-09-10 1988-09-09 Inmunoterapia tumoral empleando anticuerpos anti-idiotipicos.

Country Status (16)

Country Link
US (1) US5614610A (es)
EP (2) EP0306995B1 (es)
JP (1) JPH02494A (es)
AT (1) ATE151079T1 (es)
AU (1) AU630592B2 (es)
DE (1) DE3855850T2 (es)
DK (1) DK500888A (es)
ES (1) ES2102978T3 (es)
FI (1) FI884114A7 (es)
GR (1) GR3023725T3 (es)
HU (1) HU206394B (es)
IL (1) IL87692A (es)
NO (1) NO178464C (es)
NZ (1) NZ226129A (es)
OA (1) OA08952A (es)
PT (1) PT88459B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255209A (ja) * 1984-05-30 1985-12-16 Mitsubishi Heavy Ind Ltd 圧延機におけるエツジヤ開度制御方法
AU607533B2 (en) * 1987-08-07 1991-03-07 Xoma Corporation Methods and compositions for mimicking antigenic determinants
US6432402B1 (en) 1989-05-25 2002-08-13 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
US6805862B1 (en) 1989-05-25 2004-10-19 Sloan-Kattering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
DE69034087T2 (de) * 1989-05-25 2004-05-06 Sloan-Kettering Institute For Cancer Research Antiidiotypischer Antikörper, der ein Immunantwort gegen ein Glykosphingolipid induziert und seine Verwendung
WO1991006866A2 (en) * 1989-11-03 1991-05-16 Morton Donald L Urinary tumor associated antigen, antigenic subunits uses and methods of detection
JPH04148298A (ja) * 1990-10-08 1992-05-21 Matsushita Electric Ind Co Ltd 違法駐車検出警告装置
DE4208795A1 (de) * 1992-03-19 1993-09-23 Behringwerke Ag Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum
SE470285B (sv) * 1992-05-22 1994-01-10 Volvo Penta Ab Drivaggregat för fartyg
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US7354587B1 (en) * 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
AU5909900A (en) * 1999-07-02 2001-01-22 Life Time Pharmaceuticals, Inc. Predicting immunotherapy effectiveness through delayed type hypersensitivity
EP1221961A4 (en) * 1999-10-13 2004-03-31 Roswell Park Memorial Inst INDUCTION OF A STRONG IMMUNE RESPONSE TO A TUMOR-RELATED SELF-ANTIGEN
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
DE10352977A1 (de) * 2003-11-13 2005-06-09 Müller-Hermelink, Hans Konrad, Prof. Dr. Muriner anti Idiotyp-Antikörpers oder anti Idiotyp-Antikörper aus der Ratte des humanen monoklonalen SC-1 Antikörpers
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
JP4929864B2 (ja) 2006-06-15 2012-05-09 株式会社デンソー 配管継手装置
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
JP5985481B2 (ja) * 2010-09-01 2016-09-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗イディオタイプ抗体の迅速な産生

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720884B2 (ja) * 1983-11-07 1995-03-08 ザ・ウイスタ−・インスティテュ−ト 抗イデイオタイプ抗体によって誘発される、腫瘍およびウイルスに対する免疫応答
JPS60155133A (ja) * 1983-11-09 1985-08-15 シンビオテイツクス　コ−ポレイシヨン アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas

Also Published As

Publication number Publication date
FI884114A0 (fi) 1988-09-07
EP0306995A2 (en) 1989-03-15
FI884114L (fi) 1989-03-11
US5614610A (en) 1997-03-25
EP0306995A3 (en) 1990-03-07
NO884024D0 (no) 1988-09-09
PT88459B (pt) 1993-01-29
AU630592B2 (en) 1992-11-05
NO884024L (no) 1989-03-13
IL87692A (en) 1994-04-12
EP0759442A1 (en) 1997-02-26
DE3855850D1 (de) 1997-05-07
DE3855850T2 (de) 1997-11-20
EP0306995B1 (en) 1997-04-02
HUT47973A (en) 1989-04-28
NO178464C (no) 1996-04-03
NO178464B (no) 1995-12-27
ATE151079T1 (de) 1997-04-15
GR3023725T3 (en) 1997-09-30
FI884114A7 (fi) 1989-03-11
HU206394B (en) 1992-10-28
AU2207788A (en) 1989-03-16
NZ226129A (en) 1991-12-23
DK500888A (da) 1989-03-11
DK500888D0 (da) 1988-09-09
JPH02494A (ja) 1990-01-05
OA08952A (fr) 1990-11-30

Similar Documents

Publication Publication Date Title
ES2102978T3 (es) Inmunoterapia tumoral empleando anticuerpos anti-idiotipicos.
ES539987A0 (es) Un procedimiento para preparar un anticuerpo monoclonal hu- mano
EP0328578A4 (en) ANTIGENT RECOGNIZED BY MCA 16-88.
DK0537168T3 (da) Antigenet CTAA 28A32, som genkendes af MCA 28A32
ATE183546T1 (de) Tumorspezifischer monoklonaler antikörper 81av78
Konecny et al. Adjuvant high dose epirubicin and cyclophosphamide with G-CSF support in patients with locally advanced breast cancer
Loibner et al. Vaccination of rhesus monkeys with an anti-idiotype antibody mumicking Lewis Y: Enhancement of the anti-tumor immune response by repeated administrations of recombinant human GM-CSF.
Botzler et al. A heat inducible HSP72 associated immunogenic determinant act as a tumor specific recognition structure for NK cells
Wiesner et al. A stress inducible HSP72 cell surface expression is observed selectively on human tumor cells

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 306995

Country of ref document: ES